Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian R Wong

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Bioorganic & Medicinal Chemistry Letters|April 21, 2015
Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of Fc receptor signalingAnkush Argade, Somasekhar Bhamidipati, Hui Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 22, 2014
Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteomeHongbing Zhang, Lily I Pao, Aileen Zhou, et al.
Molecular Immunology|February 3, 2009
The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cellsKyung W Song, Francisco X Talamas, Rebecca T Suttmann, et al.
Arthritis Research & Therapy|April 3, 2016
Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritisSamuel Garcia, Linda M Hartkamp, B Malvar-Fernandez, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 2, 2006
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammationSylvia Braselmann, Vanessa Taylor, Haoran Zhao, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2008
Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivityRonald J Hill, Karim Dabbagh, Deborah Phippard, et al.
Journal of Medicinal Chemistry|March 8, 2011
Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinaseDavid M Goldstein, Michael Soth, Tobias Gabriel, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Bioorganic & Medicinal Chemistry Letters|April 21, 2015
Design, synthesis of diaminopyrimidine inhibitors targeting IgE- and IgG-mediated activation of Fc receptor signalingAnkush Argade, Somasekhar Bhamidipati, Hui Li, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 22, 2014
Deorphanization of the human leukocyte tyrosine kinase (LTK) receptor by a signaling screen of the extracellular proteomeHongbing Zhang, Lily I Pao, Aileen Zhou, et al.
Molecular Immunology|February 3, 2009
The kinase activities of interleukin-1 receptor associated kinase (IRAK)-1 and 4 are redundant in the control of inflammatory cytokine expression in human cellsKyung W Song, Francisco X Talamas, Rebecca T Suttmann, et al.
Arthritis Research & Therapy|April 3, 2016
Colony-stimulating factor (CSF) 1 receptor blockade reduces inflammation in human and murine models of rheumatoid arthritisSamuel Garcia, Linda M Hartkamp, B Malvar-Fernandez, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 2, 2006
R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammationSylvia Braselmann, Vanessa Taylor, Haoran Zhao, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 9, 2008
Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivityRonald J Hill, Karim Dabbagh, Deborah Phippard, et al.
Journal of Medicinal Chemistry|March 8, 2011
Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinaseDavid M Goldstein, Michael Soth, Tobias Gabriel, et al.
Pageof 2